Drugs / GB221
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04905667 | Nov 2019 → Sep 2020 | breast cancer | Genor Biopharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07070999 | Jan 2026 → Dec 2028 expected | spinal muscular atrophy, type 1 | Gemma Biotherapeutics | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04170595 | Mar 2014 → Dec 2021 | HER2 positive breast carcinoma | Genor Biopharma Co., Ltd. | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04164615 | Nov 2016 → Jul 2020 | HER2 positive breast carcinoma | Genor Biopharma Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GB221 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07070999 ↗ |
| Action | Inhibit | “Anti-HER2” NCT04164615 ↗ |
| Modality | Monoclonal antibody | “Recombinant Anti-HER2 Humanized Monoclonal Antibody” NCT04164615 ↗ |
| Route | Intravenous | “6 mg/kg, intravenous drip for 30\~90 minutes” NCT04164615 ↗ |